GlassScriptPhysician profile
Jean K K Calhoun
NPI 1023128774
$469.28
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.49 · 2021: $284 · 2022: $95.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $92.14 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $85.83 | 2021 | |
| Pfizer INC. | $74.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $59.98 | 2019-2021 | |
| Ucb, INC. | $49.55 | 2021 | |
| Janssen Biotech, INC. | $23.15 | 2021 | |
| Genzyme Corporation | $23.07 | 2021 | |
| Leo Pharma INC. | $18.12 | 2019 | |
| Galderma Laboratories, L.P. | $16.85 | 2021 | |
| Sun Pharmaceutical Industries INC. | $14.62 | 2021 | |
| Merck Sharp & Dohme LLC | $11.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean K Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.